Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone‐resistant prostate cancer cells and confer resistance to apoptosis

Treatment of advanced prostate cancer (PCa) relies on pharmacological or surgical androgen deprivation. However, it is only temporarily efficient. After a few months or years, the tumor relapses despite the absence of androgenic stimulation: a state referred to as hormone‐refractory prostate cancer (HRPCa). Although autophagy confers chemoresistance in some cancers, its role in the development of HRPCa remains unknown.

[1]  Yuehua Wu,et al.  AMPK-mediated autophagy is a survival mechanism in androgen-dependent prostate cancer cells subjected to androgen deprivation and hypoxia. , 2011, Cellular signalling.

[2]  Xiao-Ming Yin,et al.  Dissecting the dynamic turnover of GFP-LC3 in the autolysosome , 2011, Autophagy.

[3]  K. Ryan,et al.  Androgens modulate autophagy and cell death via regulation of the endoplasmic reticulum chaperone glucose-regulated protein 78/BiP in prostate cancer cells , 2010, Cell Death and Disease.

[4]  Sandra Barth,et al.  Autophagy: cellular and molecular mechanisms , 2010, The Journal of pathology.

[5]  M. Lotze,et al.  Autophagy inhibition in combination cancer treatment. , 2009, Current opinion in investigational drugs.

[6]  H. Scher,et al.  Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer , 2009, Clinical Cancer Research.

[7]  Johann S de Bono,et al.  Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer , 2009, Clinical Cancer Research.

[8]  A. Kimchi,et al.  Life and death partners: apoptosis, autophagy and the cross-talk between them , 2009, Cell Death and Differentiation.

[9]  M. Mudryj,et al.  Progression of prostate cancer: multiple pathways to androgen independence. , 2009, Cancer letters.

[10]  G. Kroemer,et al.  Autophagic cell death: the story of a misnomer , 2008, Nature Reviews Molecular Cell Biology.

[11]  E. Morselli,et al.  Life, death and burial: multifaceted impact of autophagy. , 2008, Biochemical Society transactions.

[12]  Lorenzo Galluzzi,et al.  To die or not to die: that is the autophagic question. , 2008, Current molecular medicine.

[13]  Guido Kroemer,et al.  Autophagy in the Pathogenesis of Disease , 2008, Cell.

[14]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Gao,et al.  Autophagy protects LNCaP cells under androgen deprivation conditions , 2008, Autophagy.

[16]  Guido Kroemer,et al.  Self-eating and self-killing: crosstalk between autophagy and apoptosis , 2007, Nature Reviews Molecular Cell Biology.

[17]  M. Shen,et al.  Pten inactivation and the emergence of androgen-independent prostate cancer. , 2007, Cancer research.

[18]  N. Mizushima,et al.  How to Interpret LC3 Immunoblotting , 2007, Autophagy.

[19]  Kenneth N Ross,et al.  Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. , 2006, Cancer research.

[20]  Y. Tsujimoto,et al.  Another way to die: autophagic programmed cell death , 2005, Cell Death and Differentiation.

[21]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[22]  Ana Maria Cuervo,et al.  Autophagy: Many paths to the same end , 2004, Molecular and Cellular Biochemistry.

[23]  L. Morel,et al.  Androgen Receptor Mediates Non-genomic Activation of Phosphatidylinositol 3-OH Kinase in Androgen-sensitive Epithelial Cells* , 2004, Journal of Biological Chemistry.

[24]  Lin Yang,et al.  Activation of Phosphatidylinositol 3-Kinase/Akt Pathway by Androgen through Interaction of p85α, Androgen Receptor, and Src* , 2003, Journal of Biological Chemistry.

[25]  A. Partin,et al.  Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. , 2001, The Urologic clinics of North America.

[26]  W. Bursch,et al.  Programmed Cell Death (PCD): Apoptosis, Autophagic PCD, or Others? , 2000, Annals of the New York Academy of Sciences.

[27]  G. Jenster,et al.  A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. , 1990, Biochemical and biophysical research communications.